The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts
The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts
分析师总结：4位专家眼中的Lyell免疫药物公司
An in-depth analysis of recent analyst...In the preceding three months, 4 analysts have released ratings for Lyell Immunopharma (NASDAQ:LYEL), presenting a wide array of perspectives from bullish to bearish.
在过去的三个月中，有4位分析师对Lyell Immunopharma（纳斯达克股票代码：LYEL）发布了评级，展示了从看好到看淡的各种观点。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表总结了他们最近的评级，展示了过去30天内不断变化的情绪，并将其与前几个月进行了比较。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $1.0, a high estimate of $1.00, and a low estimate of $1.00. Experiencing a 55.56% decline, the current average is now lower than the previous average price target of $2.25.
由分析师分析得出的12个月价格目标提供见解，平均目标价为$1.0，最高估价为$1.00，最低估价为$1.00。经历了55.56%的下跌，当前平均价低于先前的平均目标价$2.25。
Diving into Analyst Ratings: An In-Depth Exploration
深入探讨分析师评级：分析师评级的深度探讨
An in-depth analysis of recent analyst...
深入分析最近分...
登录免费看全文
登录/注册
热门讨论
中概股财报季火热：惊喜盈利能否延续涨势？
1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？
Moomoo News Global
03/04 23:26
中国两会：会议前后股票价格走势的主要要点